Pfizer Inc. $PFE Shares Acquired by GRIMES & Co WEALTH MANAGEMENT LLC

Key Points

• GRIMES & Co WEALTH MANAGEMENT LLC boosted its Pfizer stake by 647.7%, buying 684,303 shares to hold 789,950 shares worth $19.67 million at quarter-end.
• Pfizer beat Q1 estimates with $0.75 EPS (vs. $0.72) and $14.45B revenue (vs. $13.84B) and reaffirmed FY2026 guidance of 2.80–3.00 EPS (consensus ~2.98).
• Pfizer declared a quarterly dividend of $0.43 (ex-dividend May 8, payable June 12), implying a 6.5% yield but a high payout ratio of 131.3%.

GRIMES & Co WEALTH MANAGEMENT LLC increased its position in Pfizer Inc. (NYSE:PFE - Free Report) by 647.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 789,950 shares of the biopharmaceutical company's stock after buying an additional 684,303 shares during the quarter. GRIMES & Co WEALTH MANAGEMENT LLC's holdings in Pfizer were worth $19,670,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of the company. Triad Wealth Partners LLC lifted its holdings in shares of Pfizer by 1.9% in the fourth quarter. Triad Wealth Partners LLC now owns 20,466 shares of the biopharmaceutical company's stock valued at $510,000 after buying an additional 386 shares during the period. ETF Store Inc. lifted its holdings in shares of Pfizer by 3.8% in the fourth quarter. ETF Store Inc. now owns 10,913 shares of the biopharmaceutical company's stock valued at $272,000 after buying an additional 396 shares during the period. Mattern Wealth Management LLC raised its position in shares of Pfizer by 4.6% during the fourth quarter. Mattern Wealth Management LLC now owns 9,161 shares of the biopharmaceutical company's stock worth $228,000 after purchasing an additional 400 shares during the period. Pines Wealth Management LLC raised its position in shares of Pfizer by 4.4% during the fourth quarter. Pines Wealth Management LLC now owns 9,430 shares of the biopharmaceutical company's stock worth $235,000 after purchasing an additional 400 shares during the period. Finally, Quest Investment Management LLC raised its position in shares of Pfizer by 1.3% during the third quarter. Quest Investment Management LLC now owns 31,768 shares of the biopharmaceutical company's stock worth $809,000 after purchasing an additional 405 shares during the period. Institutional investors and hedge funds own 68.36% of the company's stock.

Pfizer Stock Down 0.2%

Shares of Pfizer stock opened at $26.48 on Friday. Pfizer Inc. has a 1 year low of $21.97 and a 1 year high of $28.75. The company has a market cap of $150.90 billion, a P/E ratio of 20.21 and a beta of 0.35. The company has a current ratio of 1.25, a quick ratio of 0.87 and a debt-to-equity ratio of 0.67. The stock has a 50-day moving average price of $27.14 and a 200 day moving average price of $26.16.

Pfizer (NYSE:PFE - Get Free Report) last released its earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, beating the consensus estimate of $0.72 by $0.03. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.The company had revenue of $14.45 billion for the quarter, compared to analysts' expectations of $13.84 billion. During the same quarter in the previous year, the business posted $0.92 EPS. The business's revenue for the quarter was up 5.4% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, analysts expect that Pfizer Inc. will post 2.98 EPS for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 12th. Shareholders of record on Friday, May 8th will be paid a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 6.5%. The ex-dividend date of this dividend is Friday, May 8th. Pfizer's payout ratio is 131.30%.

Key Headlines Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Q1 beat and guidance reaffirmed: Pfizer reported better-than-expected Q1 revenue and EPS and reiterated FY2026 guidance, reinforcing the company's transition beyond pandemic-driven sales and supporting near-term earnings visibility. How Pfizer’s Q1 Beat, Oncology Wins and Patent Deals At Pfizer (PFE) Has Changed Its Investment Story
• Positive Sentiment: Oncology momentum: Recent FDA approval (VEPPANU) and positive Phase 3 data (ELREXFIO) bolster Pfizer's oncology franchise, which is a key driver of longer-term growth and valuation upside. Pfizer Oncology Advances Raise New Questions For Valuation And Momentum
• Positive Sentiment: Dividend credibility restored: Coverage highlighting management's actions has reduced concerns about Pfizer being a yield trap, supporting investor confidence in the roughly 6.5% yield. Pfizer's 6.5% Dividend Yield Looked Too Good to Be True -- but Management Just Silenced the Skeptics
• Positive Sentiment: Unusual call buying: Large intraday options activity — ~254,818 calls (≈84% above normal daily call volume) — signals some traders are taking bullish, leveraged positions that could amplify upside moves if news flows remain positive.
• Neutral Sentiment: Lyme vaccine dosing trial update: A new fifth‑dose VLA15 trial was announced; it signals ongoing R&D optimization but outcome/timing uncertainty limits immediate stock impact. Pfizer’s Next Lyme Shot: What a Fifth-Dose VLA15 Trial Signals for PFE Investors
• Neutral Sentiment: Mixed analyst views and valuation debate: Analysts differ on PFE's forward momentum and valuation after Q1 — that keeps sentiment mixed and may limit large directional moves until clearer catalysts arrive. Analysts Have Conflicting Sentiments on These Healthcare Companies: Pfizer (PFE) and Compass Therapeutics (CMPX)
• Negative Sentiment: Trial termination trims oncology upside: Pfizer ended a Phase 1b/2 lymphoma combo trial, removing a small piece of future oncology optionality and introducing modest near-term disappointment for pipeline bulls. Pfizer Ends Early-Stage Lymphoma Combo Trial, Trimming a Small Piece of Its Oncology Upside

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on the company. Argus raised Pfizer from a "hold" rating to a "buy" rating and set a $35.00 target price on the stock in a research report on Monday, March 2nd. Cantor Fitzgerald reaffirmed a "neutral" rating and set a $27.00 target price on shares of Pfizer in a research report on Wednesday, February 4th. HSBC boosted their target price on Pfizer from $29.00 to $32.00 and gave the stock a "buy" rating in a research report on Tuesday, March 17th. Weiss Ratings raised Pfizer from a "hold (c-)" rating to a "hold (c)" rating in a research report on Wednesday. Finally, Morgan Stanley boosted their target price on Pfizer from $27.00 to $28.00 and gave the stock an "equal weight" rating in a research report on Friday, April 10th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, twelve have given a Hold rating and three have given a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Hold" and an average target price of $28.74.

About Pfizer

Pfizer Inc NYSE: PFE is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer's portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.